In paediatric AML and CML, HK2 has been shown to be directly targeted by miR-125a and miR-202, in this way disrupting glycolysis and, thus, overcoming chemoresistance [201,279]. This evidence concerns the gene HK2 and chronic myelogenous leukemia, BCR-ABL1 positive.